Table 3.
Inverse Probability of Treatment Weighted Adjusted Odds Ratios and 95% CIs for Biochemically Confirmed Abstinence at 3 Months
| OR | 95% CI | |
| Unadjusted | ||
| NRT | 1.0 | |
| Varenicline | 2.75 | 1.57–4.84 |
| Fully adjusteda | ||
| NRT | 1.0 | |
| Varenicline | 2.72 | 1.50–4.94 |
| Adjusted for confoundersb only | ||
| NRT | 1.0 | |
| Varenicline | 2.54 | 1.43–4.49 |
| Limited to participants without a history of depression or bipolar disorder | ||
| NRT | 1.0 | |
| Varenicline | 2.93 | 1.18–7.33 |
| Limited to participants with a BDI < 10 | ||
| NRT | 1.0 | |
| Varenicline | 2.84 | 1.25–6.46 |
| Limited to participants with a BDI < 20 | ||
| NRT | 1.0 | |
| Varenicline | 1.82 | 0.99–3.34 |
Note. BDI = Beck Depression Inventory; MCS = Mental Component Score; NRT = nicotine replacement therapy; PCS = Physical Component Score.
a
Adjusted for significant variables in Table 1 (employment, income, MCS and PCS from the SF-8, history of depression, history of bipolar disorder, Fagerström Test for Nicotine Dependence score, and decisional balance score).
b
Employment category and Mental Component Score from the SF-8.